We have convenient locations to serve you in Webster,TX and Pasadena, TX

Food and Drug Administration: (May 2022) Approved as adjunct to diet and exercise for glycemic control in adults with type 2 diabetes mellitus (November 2023) Approved for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity (December 2024) Expanded indication for moderate-to-severe obstructive sleep apnea in adults with obesity Classified as first-in-class dual GIP/GLP-1 receptor agonist Not approved for type 1 diabetes mellitus or as monotherapy in patients with history of pancreatitis International Regulatory Approvals GLP2 has received regulatory approval in multiple jurisdictions: European Union (September 2022) Type 2 diabetes treatment United Kingdom (November 2023) Expanded to include weight management Canada (November 2022) Type 2 diabetes indication Australia (December 2022) Type 2 diabetes treatment Additional regulatory reviews ongoing in other countries Warnings and Contraindications Important safety considerations include: Boxed Warning for thyroid C-cell tumor risk (based on rodent studies

These medications are FDA-approved for adults with obesity or weight-related health risks
[4] At the cellular level, free estradiol diffuses through cell membranes and binds to intracellular estrogen receptors and , which upon ligand activation dimerize and translocate to estrogen-response elements on nuclear DNA, modulating transcription of genes governing reproductive tract integrity, thermoregulation, bone metabolism, and vascular endothelial function
Extending the time between doses may lower medication levels in the body, which can reduce appetite suppression and slow progress